Endothelin-1 and human platelets

Current Vascular Pharmacology

Volumn 3, Issue 4, 2005, Pages 393-399

  Jagroop, I Anita ^a   Daskalopoulou, Stella S ^a   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bosentan; Endothelin 1; Platelet; Pulmonary hypertension; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; AMBRISENTAN; ATORVASTATIN; BOSENTAN; CLOPIDOGREL; CONJUGATED ESTROGEN; CYCLIC GMP; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ESTROGEN; FENFLURAMINE; FLUINDOSTATIN; HIRUDIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NAFTIDROFURYL; NITRIC OXIDE; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; PICOTAMIDE; PROSTACYCLIN; SARAFOTOXIN S6C; SITAXSENTAN; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; THROMBOCYTE ACTIVATING FACTOR; TIBOLONE; TICLOPIDINE; UNINDEXED DRUG;

ANTICOAGULATION; ARTERY DISEASE; BLOOD VESSEL REACTIVITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG POTENTIATION; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; MOUSE; NONHUMAN; PATHOGENESIS; PRESCRIPTION; PROTEIN INTERACTION; PULMONARY HYPERTENSION; RAT; RAYNAUD PHENOMENON; REVIEW; SEROTONINERGIC SYSTEM; SUBARACHNOID HEMORRHAGE; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE SHAPE; THROMBOCYTE VOLUME; VASCULAR DISEASE; VASODILATATION;

ANIMALS; BLOOD PLATELETS; ENDOTHELIN-1; HUMANS; PLATELET AGGREGATION; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; VASCULAR DISEASES;

EID: 24644508446     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016105774329453     Document Type: Review

References (118)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
2. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1988; 6: S188-91.
3. Khan MA, Thompson CS, Dashwood MR, Mumtaz FH, Morgan RJ, Mikhailidis DP. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr Vasc Pharmacol 2003; 1: 27-31.
4. Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol Pharm Bull 2001; 24: 1219-30.
5. Bousette N, Giaid A. Endothelin-1 in atherosclerosis and other vasculopathies. Can J Physiol Pharmacol 2003; 81: 578-87.
6. Touyz RM, Lariviere R, Schiffrin EL. Endothelin influences pHi of human platelets through protein kinase C mediated pathways. Thromb Res 1995; 78: 55-65.
7. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. J Cardiovasc Pharmacol 2000; 35(4 Suppl 2): S37-40.
8. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-54.
9. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to the total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 936-8.
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
11. Peripheral Arterial Diseases Antiplatelet Consensus Group. Anti-platelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 2003; 26: 1-16.
12. Tsikouris JP, Simoni J, Suarez JA, Sutthiwan P, Ziska M, Meyerrose GE. Comparison of effects of quinapril versus enalapril on vasoactive substances following acute myocardial infarction. Am J Cardiol 2004; 94: 641-3, A9.
13. Syvolap VD, Pivovarov SN, Syvolap VV. [Endothelin-1 level in the complicated course of myocardial infarction]. Lik Sprava 2002; (2): 139-40.
14. Vojacek J, Kolar J, Lisy O, Hrabos V, Simek S, Jindra A, Jr. et al. Time course of endothelin-1 plasma level in patients with acute coronary syndromes. Cardiology 1999; 91: 114-8.
15. Battistelli S, Billi M, Manasse G, Vittoria A, Roviello F, Forconi S. Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction. Angiology 1999; 50; 629-38.
16. Qiu S, Theroux P, Marcil M, Solymoss BC. Plasma endothelin-1 levels in stable and unstable angina. Cardiology 1993; 82: 12-9.
17. Borries M, Heins M, Fischer Y, Stiegler H, Schoebel FC, Reinauer H, et al. [Endothelin and big endothelin in coronary heart disease and acute coronary syndromes]. Z Kardiol 1996; 85: 761-7.
18. Mikhailidis DP, Barradas MA, Mier A, Boag F, Jeremy JY, Havard CWH, et al. Platelet function in patients admitted with a diagnosis of myocardial infarction. Angiology 1987; 38: 36-45.
19. Li JJ. Circadian variation in myocardial ischemia: the possible mechanisms involving in this phenomenon. Med Hypotheses 2003; 61: 240-3.
20. Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991; 18: 38-43.
21. Aoki Y, Saji T. [Nitric oxide and endothelins in pulmonary hypertension]. Nippon Rinsho 2001; 59: 1059-64.
22. Brunner HR. Endothelin inhibition as a biologic target for treating hypertension. Am J Hypertens 1998; 11(4 Pt 3): 103S-9S.
23. Gildea TR, Arroliga AC, Minai OA. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension. Cleve Clin J Med 2003; 70 (Suppl 1): S18-27.
24. Molnar C, Alber H, Colleselli D, Vogel W, Kahler CM. Successful switch from inhalative iloprost to oral bosentan, in portopulmonary hypertension associated with liver cirrhosis. Wien Klin Wochenschr 2004; 116: 627-30.
25. Ortega MA, de Artinano AA. Highlights on endothelins: a review. Pharmacol Res 1997; 36: 339-51.
26. Kelly JJ, Whitworth JA. Endothelin-1 as a mediator in cardiovascular disease. Clin Exp Pharmacol Physiol 1999; 26: 158-61.
27. Mukerjee D, Yap LB, Ong V, Denton CP, Howells K, Black CM, et al. The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension. Ann Rheum Dis 2004; 63: 1627-31.
28. Parker JD, Thiessen JJ. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol 2004; 286: H1141-5.
29. Kinugawa T, Kato M, Ogino K, Osaki S, Igawa O, Hisatome I, et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J Card Fail 2003; 9: 318-24.
30. Hutton RA, Mikhailidis DP, Bernstein RM, Jeremy JY, Hughes GRV, Dandona P. An assessment of platelet function in patients with Raynaud's syndrome. J Clin Pathol 1984; 37: 182-7.
31. Dorhout Mees SM, Rinkel GJ, Hop JW, Algra A, van Gijn J. Antiplatelet therapy in aneurysmal subarachnoid hemorrhage: a systematic review. Stroke 2003; 34: 2285-9.
32. Schafer A, Eigenthaler M, Bauersachs J. Platelet activation in heart failure. Clin Lab 2004; 50: 559-66.
33. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E. Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003; 60 (Suppl 1): S13-21.
34. Heintz B, Schmidt P, Maurin N, Kirsten R, Nelson K, Wieland D, et al. Endothelin-1 potentiates ADP-induced platelet aggregation in chronic renal failure. Ren Fail 1994; 16: 481-9.
35. Ergul A, Johansen JS, Stromhaug C, Harris AK, Hutchinson J, Tawfik A, et al. Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: role of endothelin-1. J Pharmacol Exp Ther 2005; 313: 70-7.
36. Radeau T, Lebel M, Houde I, Lariviere R, Mauriege P, Kingma I, et al. Endothelin-1 levels and cardiovascular risk factors in renal transplant patients. Clin Biochem 2004; 37: 1072-8.
37. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004; 53: 2060-6.
38. Karter Y, Aydin S, Curgunlu A, Uzun H, Erturk N, Vehid S, et al. Endothelium and angiogenesis in white coat hypertension. J Hum Hypertens 2004; 18: 809-14.
39. Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T, et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004; 53: 550-5.
40. Regitz-Zagrosek V. Cardiovascular disease in postmenopausal women. Climacteric 2003; 6 (Suppl 3): 13-20.
41. Economides PA, Caselli A, Tiani E, Khaodhiar L, Horton ES, Veves A. The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 740-7.
42. Kalogeropoulou K, Mortzos G, Migdalis I, Velentzas C, Mikhailidis DP, Georgiadis E, et al. Carotid atherosclerosis in type 2 diabetes mellitus: potential role of endothelin-1, lipoperoxides, and prostacyclin. Angiology 2002; 53: 279-85.
43. Mangiafico RA, Malatino LS, Santonocito M, Spada RS. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol 1998; 17: 97-102.
44. Jagroop IA, Berwanger CS, Stansby G, Mikhailidis DP. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol 1999; 18: 77-9.
45. Stojanovic ND, Kwong P, Byrne DJ, Arnold A, Jagroop IA, Nair D, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54: 391-9.
46. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77: 945-51.
47. Anwaar I, Rendell M, Gottsater A, Lindgarde F, Hulthen UL, Mattiasson I. Hormone replacement therapy in healthy postmenopausal women. Effects on intraplatelet cyclic guanosine monophosphate, plasma endothelin-1 and neopterin. J Intern Med 2000; 247: 463-70.
48. Gottsater A, Anwaar I, Lind P, Mattiasson I, Lindgarde F. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis 1999; 10: 133-40.
49. Lopez-Farre A, Caramelo C, Esteban A, Alberola ML, Millas I, Monton M, et al. Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation 1995; 91: 2080-8.
50. Leung SW, Man GS, Man RY. Platelet-activating factor enhanced the pressor response of endothelin-1. J Cardiovasc Pharmacol 2002; 40: 528-32.
51. Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res 1998; 92: 119-23.
52. Turunen P, Mikkola T, Ylikorkala O, Viinikka L. Hirudin stimulates prostacyclin but not endothelin-1 production in cultured human vascular endothelial cells. Thromb Res 1996; 81: 635-40.
53. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
54. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl S): 62S-7S.
55. Talbodec A, Berkane N, Blandin V, Breittmayer JP, Ferrari E, Frelin C, et al. Aspirin and sodium salicylate inhibit endothelin ETA receptors by an allosteric type of mechanism. Mol Pharmacol 2000; 57: 797-804.
56. Blandin V, Vigne P, Breittmayer JP, Frelin C. Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid. Mol Pharmacol 2000; 58: 1461-9.
57. Barden A, Beilin LJ, Ritchie J, Walters BN, Michael CA. Plasma and urinary endothelin 1, prostacyclin metabolites and platelet consumption in pre-eclampsia and essential hypertensive pregnancy. Blood Press 1994; 3: 38-46.
58. Clark BA, Ludmir J, Epstein FH, Alvarez J, Tavara L, Bazul J, et al. Urinary cyclic GMP, endothelin, and prostaglandin E2 in normal pregnancy and preeclampsia. Am J Perinatol 1997; 14: 559-62.
59. Nadar S, Lip GY. Platelet activation in the hypertensive disorders of pregnancy. Expert Opin Investig Drugs 2004; 13: 523-9.
60. Puddu P, Puddu GM, Cravero E, Muscari A. Different effects of antihypertensive drugs on endothelial dysfunction. Acta Cardiol 2004; 59: 555-64.
61. Gossl M, Mitchell A, Lerman A, Opazo SA, Schafers RF, Erbel R, et al. Endothelin-B-receptor-selective antagonist inhibits endothelin-1 induced potentiation on the vasoconstriction to noradrenaline and angiotensin II. J Hypertens 2004; 22: 1909-16.
62. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Human Hypertens 2000; 14: 581-85.
63. Yang Z, Krasnici N, Luscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999; 100: 5-8.
64. Hirahashi J, Nakaki T, Hishikawa K, Marumo T, Hayashi M, Saruta T. Endothelin ET(A) receptor antagonist reverses the inhibitory effect of platelet-derived growth factor on cytokine-induced nitric oxide production. Euro J Pharmacol 2005; 366: 119-23.
65. Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004; 43: 1089-115.
66. Dandel M, Hetzer R. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension. Curr Vasc Pharmacol 2003; 1: 171-81.
67. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22: 451-8.
68. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999; 54: 161-8.
69. Barradas MA, Mikhailidis AM, Mikhailidis DP, Dandona P. The effects of fenfluramine on platelet aggregation. Br J Clin Pharmacol 1982; 14: 466-8.
70. Barradas MA, Mikhailidis DP, Dandona P. The effect of fenfluramine on collagen-induced platelet aggregation in vitro. Br J Clin Pharmacol 1983; 16: 459.
71. Jagroop IA, Mikhailidis DP. An investigation of the serotoninergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 2000; 11: 161-5.
72. Yousufzai SY, Abdel-latif AA. Endothelin-1 stimulates the release of arachidonic acid and prostaglandins in cultured human ciliary muscle cells: activation of phospholipase A2. Exp Eye Res 1997; 65: 73-81.
73. Jagroop IA, Mikhailidis DP. Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl. Platelets 2000; 11: 272-7.
74. Barradas MA, O'Donoghue S, Mikhailidis DP. Measurement of platelet volume using a channelyzer: assessment of the effect of agonists and antagonists. In Vivo 1992; 6: 629-34.
75. Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 2000; 11: 28-32.
76. Mikkola T, Ristimaki A, Viinikka L, Ylikorkala O. human serum, plasma, and platelets stimulate prostacyclin and endothelin-1 synthesis in human vascular endothelial cells. Life Sci 1993; 53: 283-89.
77. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787-800
78. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988;18:399-404.
79. Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease. In Vivo 1993; 7: 543-8.
80. Barradas MA, Jagroop IA, Mikhailidis DP. Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. Clin Chim Acta 1994; 230: 157-67.
81. Pietraszek MH, Takada Y, Takada A. Endothelins inhibit serotonin-induced platelet aggregation via a mechanism involving protein kinase C. Eur J Pharmacol 1992; 219: 289-93.
82. Liras A, Catalan RE, Martinez AM. Synergistic effect of endothelin-1 and serotonin in rabbit platelets: effect on tyrosine phosphorylation. Thromb Res 2000; 100: 325-31.
83. Knofler R, Urano T, Malyszko J, Takada Y, Takada A. In vitro effect of endothelin-1 on collagen, and ADP-induced aggregation in human whole blood and platelet rich plasma. Thromb Res 1995; 77: 69-78.
84. Dockrell ME, Webb DJ, Williams BC. Activation of the endothelin B receptor causes a dose-dependent accumulation of cyclic GMP in human platelets. Blood Coagul Fibrinolysis 1996; 7: 178-80.
85. McMurdo L, Lidbury PS, Thiemermann C, Vane JR. Mediation of endothelin-1-induced inhibition of platelet aggregation via the ETB receptor. Br J Pharmacol 1993; 109: 530-4.
86. Touyz RM, Schiffrin EL. Role of protein kinase C in the anti-aggregatory effects of endothelin-1 on human platelets. Clin Sci (Lond) 1995; 88: 277-83.
87. Pawlak K, Malyszko JS, Malyszko J, Mysliwiec M. Effects of endothelin-1 on aggregation of normal and uremic platelets. Pol J Pharmacol 1996; 48: 185-90.
88. Dockrell ME, Walker BR, Noon JP, Watt GC, Williams BC, Webb DJ. Platelet aggregation in young men with contrasting predisposition to high blood pressure. Am J Hypertens 1999; 12(2 Pt 1): 115-9.
89. Halim A, Kanayama N, el Maradny E, Maehara K, Hirano M, Kobayashi T, et al. Endothelin-1 evoked an increase and oscillations in cytosolic calcium concentration in adherent single human platelets and increased GMP-140 (P-selectin) in platelet suspension. Thromb Res 1995; 80: 105-12.
90. Helset E, Lindal S, Olsen R, Myklebust R, Jorgensen L. Endothelin-1 causes sequential trapping of platelets and neutrophils in pulmonary microcirculation in rats. Am J Physiol 1996; 271(4 Pt 1): L538-46.
91. Joseph R, Scicli AG, Han E, Grunfeld S, Carretero OA, Welch KM. Endothelin-1 and human platelet activity. Thromb Res 1991; 61; 529-36.
92. Luscher TF, Tanner FC, Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr Opin Lipidol 1996; 7: 234-40.
93. Astarie-Dequeker C, Iouzalen L, David-Dufilho M, Devynck MA. In vitro inhibition by endothelins of thrombin-induced aggregation and Ca2+ mobilization in human platelets. Br J Pharmacol 1992; 106: 966-71.
94. Vlachojannis J, Tsakas S, Chinari E, Orphanos V, Zoumbos N, Kurz P. Increased endothelin-1 content in the platelets of hemodialysed patients. Clin Nephrol 1997; 48: 185-90.
95. Kato K, Sawada S, Toyoda T, Kobayashi K, Shirai K, Yamamoto K, et al. Influence of endothelin on human platelet aggregation and prostacyclin generation from human vascular endothelial cells in culture. Jpn Circ J 1992; 56: 422-31.
96. Sudjarwo SA, Hori M, Tanaka T, Matsuda Y, Okada T, Karaki H. Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction. Biochem Biophys Res Commun 1994; 200: 627-33.
97. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol 1993; 110: 777-82.
98. Uhlmann D, Glasser S, Gaebel G, Armann B, Ludwig S, Tannapfel A, et al. Improvement of postischemic hepatic microcirculation after endothelin(A) receptor blockade-endothelin antagonism influences platelet-endothelium interactions. J Gastrointest Surg 2005; 9: 187-97.
99. Cywes R, Packham MA, Tietze L, Sanabria JR, Harvey PR, Phillips MJ, et al. Role of platelets in hepatic allograft preservation injury in the rat. Hepatology 1993; 18: 635-47.
100. Yadav SS, Howell DN, Steeber DA, Harland RC, Tedder TF, Clavien PA. P-Selectin mediates reperfusion injury through neutrophil and platelet sequestration in the warm ischemic mouse liver. Hepatology 1999; 29: 1494-502.
101. Saitta A, Sardo A, Bonaiuto M, Giordano G, Imbalzano E, Castaldo M, et al. Effects of picotamide on release of endothelin-1, thromboxane and prostacycline after treadmill stress in patients with peripheral artery disease. Angiology 1998; 49: 879-84.
102. Filep JG, Herman F, Battistini B, Chabrier PE, Braquet P, Sirois P. Antiaggregatory and hypotensive effects of endothelin-1 in beagle dogs: role for prostacyclin. J Cardiovasc Pharmacol 1991; 17 (Suppl 7): S216-8.
103. Ohtsuka S. Changes of vasoactive peptides and effects of inhaled nitric oxide after pneumonectomy. Kurume Med J 1996; 43: 295-304.
104. Battistini B, Sirois P, Braquet P, Filep JG. Endothelin-induced constriction of guinea pig airways: role of platelet-activating factor. Eur J Pharmacol 1990; 186: 307-10.
105. Filep JG, Battistini B, Sirois P. Endothelin induces thromboxane release and contraction of isolated guinea-pig airways. Life Sci 1990; 47: 1845-50.
106. Filep JG, Battistini B, Sirois P. Induction by endothelin-1 of epithelium-dependent relaxation of guinea-pig trachea in vitro: role for nitric oxide. Br J Pharmacol 1993; 109: 637-44.
107. Lueddeckens G, Bigl H, Sperling J, Becker K, Braquet P, Forster W. Importance of secondary TXA2 release in mediating of endothelin-1 induced bronchoconstriction and vasopressin in the guinea-pig. Prostagl Leukot Essent Fatty Acids 1993; 48: 261-3.
108. Ajayi AA, Ogungbade GO, Hercule HC, Oyekan AO, Mutembei L. Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA(2) mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats. Diabetes Res Clin Pract 2004; 63: 155-69.
109. Callera GE, Montezano AC, Touyz RM, Zorn TM, Carvalho MH, Fortes ZB, et al. ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension 2004; 43: 872-9.
110. Ikeda M, Kohno M, Horio T, Yasunari K, Yokokawa K, Kano H, et al. Effect of thrombin and PDGF on endothelin production in cultured mesangial cells derived from spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 22: S197-8.
111. Khimenko PL, Moore TM, Taylor AE. Blocked ETA receptors prevent ischemia and reperfusion injury in rat lungs. J Appl Physiol 1996; 80: 203-7.
112. Kita S, Matsumura Y, Tanida Y, Kusuno T, Chatani S, Taguchi Y, et al. Platelets enhance contractility in perfused rat mesenteric arteries: involvement of endothelin-1. Eur J Pharmacol 1997; 340: 209-15.
113. Mustafa SB, Gandhi CR, Harvey SA, Olson MS. Endothelin stimulates platelet-activating factor synthesis by cultured rat Kupffer cells. Hepatology 1995; 21: 545-53.
114. Brochu I, Labonte J, Bkaily G, D'Orleans-Juste P. Role of endothelin receptors in the hypertensive state of kinin B(2) knockout mice subjected to a high-salt diet. Clin Sci (Lond) 2002; 103 Suppl 48:380S-384S.
115. Labonte J, Brochu I, Honore JC, D'Orleans-Juste P. Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse. Br J Pharmacol 2001; 132: 934-40.
116. McMurdo L, Thiemermann C, Vane JR. The endothelin ETB receptor agonist, IRL 1620, causes vasodilatation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit. Eur J Pharmacol 1994; 259: 51-5.
117. Kohno M, Horio T, Yokokawa K, Yasunari K, Kurihara N, Takeda T. Endothelin modulates the mitogenic effect of PDGF on glomerular mesangial cells. Am J Physiol 1994; 266: F894-900.
118. Tozum TF, Demiralp B. Platelet-rich plasma: a promising innovation in dentistry. J Can Dent Assoc 2003; 69: 664-664h.